Study of Nilotinib in Metastatic Melanoma With KIT Aberrations
NCT01099514
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Melanoma With KIT Aberration
Interventions
DRUG:
Nilotinib
Sponsor
Samsung Medical Center